Información del artículo
Abstract
Peritoneal carcinomatosis, without special treatment, is a fatal sign of gastrointestinal and gynaecological malignancy. Cytoreductive surgery to remove gross disease is combined with perioperative intraperitoneal and intravenous chemotherapy to eradicate the residual microscopic disease. Knowledge of the effect of the peritoneal barrier on the pharmacokinetics of the chemotherapy agents, and the factors that affect this, enables a good combination of drugs, dosage and solution volume to be selected, in order to predict peritoneal and systemic exposure to the treatment and its toxicity. Timing of the chemotherapy as a planned part of the surgical procedure to maximise exposure of all peritoneal surfaces is crucial to success. In this article we update the pharmacokinetic basis for perioperative chemotherapy treatment of peritoneal carcinomatosis of gastrointestinal or gynaecological origin.
Keywords:
Intraperitoneal chemotherapy
Peritoneal-plasma barrier
Appendiceal cancer
Colorectal cancer
Peritoneal mesothelioma
Ovarian cancer
Resumen
En los tumores digestivos y ginecológicos, la carcinomatosis peritoneal, sin tratamientos especiales, es una manifestación fatal de estas enfermedades. La cirugía citorreductora, que extirpa la enfermedad microscópica, se combina con quimioterapia perioperatoria intraperitoneal e intravenosa para eliminar la enfermedad microscópica residual. Entender bien el efecto de la membrana peritoneal en la farmacocinética de los quimioterápicos y los factores que la modifican permite elegir la combinación de fármacos, calcular su dosis y el volumen de disolución, lo que facilita predecir la exposición peritoneal y sistémica al tratamiento y su toxicidad. Coordinar la quimioterapia como una parte programada del tratamiento quirúrgico para obtener la máxima exposición en toda la superficie peritoneal es crucial para el éxito del tratamiento. En este artículo actualizamos las bases farmacocinéticas de la quimioterapia perioperatoria de la carcinomatosis peritoneal.
Palabras clave:
Quimioterapia intraperitoneal
Barrera peritoneoplasmática
Cáncer de apéndice
Cáncer colorrectal
Mesotelioma peritoneal
Cáncer de ovario
El Texto completo está disponible en PDF
References
[1.]
D.G. Jayne, S. Fook, C. Loi, F. Seow-Choen.
Peritoneal carcinomatosis from colorectal cancer.
Br J Surg, 89 (2002), pp. 1545-1550
[2.]
J.T. Brodsky, A.M. Cohen.
Peritoneal seeding following potentially curative resection of colonic carcinoma: implications for adjuvant therapy.
Dis Colon Rectum, 34 (1991), pp. 723-728
[3.]
D.Z. Chu, N.P. Lang, C. Thompson, P.K. Osteen, K.C. Westbrook.
Peritonal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors.
Cancer, 63 (1989), pp. 364-367
[4.]
B. Sadeghi, C. Arvieux, O. Glehen, A.C. Beaujard, M. Rivoire, J. Baulieux, et al.
Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study.
Cancer, 88 (2000), pp. 358-363
[5.]
A. de Gramont, A. Figer, M. Seymour, M. Homerin, A. Hmissi, J. Cassidy, et al.
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
J Clin Oncol, 18 (2000), pp. 2938-2947
[6.]
J.Y. Douillard, D. Cunningham, A.D. Roth, M. Navarro, R.D. James, P. Karasek, et al.
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
Lancet, 355 (2000), pp. 1041-1047
[7.]
H. Hurwitz, L. Fehrenbacher, W. Novotny, T. Cartwright, J. Hainsworth, W. Heim, et al.
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
N Engl J Med, 350 (2004), pp. 2335-2342
[8.]
J.S. Spratt, R.A. Adcock, M. Muskovin, W. Sherrill, J. McKeown.
Clinical delivery system for intraperitoneal hyperthermic chemotherapy.
Cancer Res, 40 (1980), pp. 256-260
[9.]
K.L. Speyer, C.E. Meyers.
The use of peritoneal dialysis for delivery of chemotherapy to intraperitoneal malignancies.
Recent Results Cancer Res, 74 (1980), pp. 264-269
[10.]
S. Koga, N. Shimizu, M. Maeta, R. Hamazoe, A. Izumi.
Application of heat combined with antineoplastic agent administration in the treatment of cancer (with special reference to malignancy of the digestive system).
Gan To Kagaku Ryoho, 10 (1983), pp. 358-365
[11.]
O. Glehen, F. Mithieux, D. Osinsky, A.C. Beaujard, G. Freyer, P. Guertsch, et al.
Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal carcinomatosis: a phase II study.
J Clin Oncol, 21 (2003), pp. 799-806
[12.]
D. Elias, F. Blot, A. El Otmany, S. Antoun, P. Lasser, V. Boige, et al.
Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy.
Cancer, 92 (2001), pp. 71-76
[13.]
O. Glehen, F.N. Gilly, P.H. Sugarbaker.
New perspectives in the management of colorectal cancer: what about peritoneal carcinomatosis?.
Scand J Surg, 92 (2003), pp. 178-179
[14.]
P. Shen, E.A. Levine, J. Hall, D. Case, G. Russell, R. Fleming, et al.
Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis.
Arch Surg, 138 (2003), pp. 26-33
[15.]
S.R. Pestieau, P.H. Sugarbaker.
Treatment of primary colon cancer with peritoneal carcinomatosis: comparison of concomitant vs. delayed management.
Dis Colon Rectum, 43 (2000), pp. 1341-1346
[16.]
A.J. Witkamp, E. de Bree, M.M. Kaag, H. Boot, J.H. Beijnen, G.W. van Slooten, et al.
Extensive cytoreductive surgery followed by intra-operative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin.
Eur J Cancer, 37 (2001), pp. 979-984
[17.]
V.J. Verwaal, S. Bruin, H. Boot, G. van Slooten, T. van, H. interen.
8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer.
Ann Surg Oncol, (2008),
[18.]
O. Glehen, F. Kwiatkowski, P.H. Sugarbaker, D. Elias, E.A. Levine, M. De Simone, et al.
Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study.
J Clin Oncol, 22 (2004), pp. 3284-3292
[19.]
T.D. Yan, D. Black, P.H. Sugarbaker, J. Zhu, Y. Yonemura, G. Petrou, et al.
A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer.
Ann Surg Oncol, 14 (2007), pp. 2702-2713
[20.]
L. Bijelic, A. Jonson, P.H. Sugarbaker.
Systematic review of cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis in primary and recurrent ovarian cancer.
Ann Oncol, 18 (2007), pp. 1943-1950
[21.]
T.D. Yan, L. Welch, D. Black, P.H. Sugarbaker.
A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma.
Ann Oncol, 18 (2007), pp. 827-834
[22.]
T.D. Yan, D. Black, R. Savady, P.H. Sugarbaker.
A systematic review on the efficacy of cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei.
Ann Surg Oncol, 14 (2007), pp. 484-492
[23.]
T.D. Yan, D. Black, R. Savady, P.H. Sugarbaker.
Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma.
J Clin Oncol, 24 (2006), pp. 4011-4019
[24.]
P.H. Sugarbaker.
Peritonectomy procedures.
Surg Oncol Clin North Am, 12 (2003), pp. 703-727
[25.]
M.A. Baron.
Structure of the intestinal peritoneum in man.
Am J Anat, 69 (1941), pp. 439-497
[26.]
J.W. Dobbie.
Utrastructure and pathology of the peritoneum in peritoneal dialysis.
Textbook of peritoneal dialysis, pp. 17-45
[27.]
P.H. Sugarbaker.
Peritoneum as the first-line of defense in carcinomatosis.
J Surg Oncol, 95 (2007), pp. 93-96
[28.]
S.J. Oosterling, G.J. van der Bij, M. van Egmond, J.R. van der Sijp.
Surgical trauma and peritoneal recurrence of colorectal carcinoma.
Eur J Surg Oncol, 31 (2005), pp. 29-37
[29.]
R.L. Dedrick, C.E. Myers, P.M. Bungay, V.T. DeVita Jr.
Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer.
Cancer Treat Rep, 62 (1978), pp. 1-11
[30.]
P.H. Sugarbaker, J.T. Mora, P. Carmignani, O.A. Stuart, D. Yoo.
Update on chemotherapeutic agents utilized for perioperative intraperitoneal chemotherapy.
Oncologist, 10 (2005), pp. 112-122
[31.]
M.F. Flessner.
The transport barrier in intraperitoneal therapy.
Am J Physiol Renal Physiol, 288 (2005), pp. F433-F442
[32.]
M.H. Katz, R.M. Barone.
The rationale of perioperative intraperitoneal chemotherapy in the treatment of peritoneal surface malignancies.
Surg Oncol Clin North Am, 12 (2003), pp. 673-688
[33.]
R.L. Dedrick, M.F. Flessner.
Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure.
J Natl Cancer Inst, 89 (1997), pp. 480-487
[34.]
G. Los, P.H. Mutsaers, W.J. Lenglet, G.S. Baldew, J.G. McVie.
Platinum distribution in intraperitoneal tumors after intraperitoneal cisplatin treatment.
Cancer Chemother Pharmacol, 25 (1990), pp. 389-394
[35.]
G. Los, E.M. Verdegaal, P.H. Mutsaers, J.G. McVie.
Penetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy.
Cancer Chemother Pharmacol, 28 (1991), pp. 159-165
[36.]
R.F. Ozols, G.Y. Locker, J.H. Doroshow, K.R. Grotzinger, C.E. Myers, R.C. Young.
Pharmacokinetics of adriamycin and tissue penetration in murine ovarian cancer.
Cancer Res, 39 (1979), pp. 3209-3214
[37.]
P. Esquis, D. Consolo, G. Magnin, P. Pointaire, P. Moretto, M.D. Ynsa, et al.
High intra-abdominal pressure enhances the penetration and antitumor effect of intraperitoneal cisplatin on experimental peritoneal carcinomatosis.
Ann Surg, 244 (2006), pp. 106-112
[38.]
P. Jacquet, O.A. Stuart, D. Chang, P.H. Sugarbaker.
Effects of intra-abdominal pressure on pharmacokinetics and tissue distribution of doxorubicin after intraperitoneal administration.
Anticancer Drugs, 7 (1996), pp. 596-603
[39.]
M. Flessner, J. Henegar, S. Bigler, L. Genous.
Is the peritoneum a significant transport barrier in peritoneal dialysis?.
Perit Dial Int, 23 (2003), pp. 542-549
[40.]
V. de Lima Vazquez, O.A. Stuart, F. Mohamed, P.H. Sugarbaker.
Extent of parietal peritonectomy does not change intraperitoneal chemotherapy pharmacokinetics.
Cancer Chemother Pharmacol, 52 (2003), pp. 108-112
[41.]
P. Jacquet, A. Averbach, A.D. Stephens, O.A. Stuart, D. Chang, P.H. Sugarbaker.
Heated intraoperative intraperitoneal mitomycin C and early postoperative intraperitoneal 5-fluorouracil: pharmacokinetic studies.
Oncology, 55 (1998), pp. 130-138
[42.]
G. Stelin, B. Rippe.
A phenomenological interpretation of the variation in dialysate volume with dwell time in CAPD.
Kidney Int, 38 (1990), pp. 465-472
[43.]
R.P. Sticca, B.W. Dach.
Rationale for hyperthermia with intraoperative intraperitoneal chemotherapy agents.
Surg Oncol Clin North Am, 12 (2003), pp. 689-701
[44.]
O. Dahl, R. Dalene, B.C. Schem, O. Mella.
Status of clinical hyperthermia.
Acta Oncol, 38 (1999), pp. 863-873
[45.]
J.R. Lepock.
How do cells respond to their thermal environment?.
Int J Hyperthermia, 21 (2005), pp. 681-687
[46.]
G.M. Hahn, J. Braun, I. Har-Kedar.
Thermochemotherapy: synergism between hyperthermia (42–43 degrees) and adriamycin (of bleomycin) in mammalian cell inactivation.
Proc Natl Acad Sci U S A, 72 (1975), pp. 937-940
[47.]
T. Kusumoto, S.A. Holden, G. Ara, B.A. Teicher.
Hyperthermia and platinum complexes: time between treatments and synergy in vitro and in vivo.
Int J Hyperthermia, 11 (1995), pp. 575-586
[48.]
B. Barlogie, P.M. Corry, B. Drewinko.
In vitro thermochemotherapy of human colon cancer cells with cis-dichlorodiammineplatinum(II) and mitomycin C.
Cancer Res, 40 (1980), pp. 1165-1168
[49.]
M. Urano, C.C. Ling.
Thermal enhancement of melphalan and oxaliplatin cytotoxicity in vitro.
Int J Hyperthermia, 18 (2002), pp. 307-315
[50.]
F. Mohamed, P. Marchettini, O.A. Stuart, M. Urano, P.H. Sugarbaker.
Thermal enhancement of new chemotherapeutic agents at moderate hyperthermia.
Ann Surg Oncol, 10 (2003), pp. 463-468
[51.]
L. Benoit, C. Duvillard, P. Rat, B. Chauffert.
Effects de la température intra-abdominale sur la diffusion tissulaire et tumorale du cisplatine intrapéritonéal dans un modèle de carcinose péritonéale chez le rat.
Chirurgie, 124 (1999), pp. 375-379
[52.]
P. Jacquet, A. Averbach, O.A. Stuart, D. Chang, P.H. Sugarbaker.
Hyperthermic intraperitoneal doxorubicin: pharmacokinetics, metabolism, and tissue distribution in a rat model.
Cancer Chemother Pharmacol, 41 (1998), pp. 147-154
[53.]
A. Garofalo, M. Valle, J. Garcia, P.H. Sugarbaker.
Laparoscopic intraperitoneal hyperthermic chemotherapy for palliation of debilitating malignant ascites.
Eur J Surg Oncol, 32 (2006), pp. 682-685
[54.]
E. Facchiano, S. Scaringi, R. Kianmanesh, J.M. Sabate, B. Castel, Y. Flamant, et al.
Laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of malignant ascites secondary to unresectable peritoneal carcinomatosis from advanced gastric cancer.
Eur J Surg Oncol, 34 (2008), pp. 154-158
[55.]
S.R. Pestieau, K.J. Schnake, O.A. Stuart, P.H. Sugarbaker.
Impact of carrier solutions on pharmacokinetics of intraperitoneal chemotherapy.
Cancer Chemother Pharmacol, 47 (2001), pp. 269-276
[56.]
F. Mohamed, P. Marchettini, O.A. Stuart, P.H. Sugarbaker.
Pharmacokinetics and tissue distribution of intraperitoneal paclitaxel with different carrier solutions.
Cancer Chemother Pharmacol, 52 (2003), pp. 405-410
[57.]
F. Mohamed, P.H. Sugarbaker.
Carrier solutions for intraperitoneal chemotherapy.
Surg Oncol Clin North Am, 12 (2003), pp. 813-824
[58.]
D. Elias, A. El Otmany, M. Bonnay, A. Paci, M. Ducreux, S. Antoun, et al.
Human pharmacokinetic study of heated intraperitoneal oxaliplatin in increasingly hypotonic solutions after complete resection of peritoneal carcinomatosis.
Oncology, 63 (2002), pp. 346-352
[59.]
B. Chauffert, P. Favoulet, E. Polycarpe, C. Duvillard, J.L. Beltramo, F. Bichat, et al.
Rationale supporting the use of vasoconstrictors for intraperitoneal chemotherapy with platinum derivatives.
Surg Oncol Clin North Am, 12 (2003), pp. 835-848
[60.]
W.D. Ensminger, J.W. Gyves.
Regional chemotherapy of neoplastic diseases.
Pharmacol Ther, 21 (1983), pp. 277-293
[61.]
P. Favoulet, G. Magnin, J.C. Guilland, J.L. Beltramo, L. Osmak, L. Benoit, et al.
Pre-clinical study of the epinephrine-cisplatin association for the treatment of intraperitoneal carcinomatosis.
Eur J Surg Oncol, 27 (2001), pp. 59-64
[62.]
C. Molucon-Chabrot, N. Isambert, L. Benoit, S. Zanetta, J. Fraisse, et al.
Feasibility of using intraperitoneal epinephrine and cisplatin in patients with advanced peritoneal carcinomatosis.
Anticancer Drugs, 17 (2006), pp. 1211-1217
[63.]
P. Lindnér, D. Heath, S. Howell, P. Naredi, L. Hafström.
Vasopressin modulation of peritoneal, lymphatic, and plasma drug exposure following intraperitoneal administration.
Clin Cancer Res, 2 (1996), pp. 311-317
[64.]
J. Rubin, M. Clawson, A. Planch, Q. Jones.
Measurements of peritoneal surface area in man and rat.
Am J Med Sci, 295 (1988), pp. 453-458
[65.]
P.H. Sugarbaker, O.A. Stuart, C.P. Carmignani.
Pharmacokinetic changes induced by the volume of chemotherapy solution in patients treated with hyperthermic intraperitoneal mitomycin C.
Cancer Chemother Pharmacol, 57 (2006), pp. 703-708
[66.]
S. Fujimoto, R.D. Shrestha, M. Kokubun, K. Kobayashi, S. Kiuchi, C. Konno, et al.
Positive results of combined therapy of surgery and intraperitoneal hyperthermic perfusion for far-advanced gastric cancer.
Ann Surg, 212 (1990), pp. 592-596
[67.]
T. Fujimura, Y. Yonemura, S. Fushida, M. Urade, S. Takegawa, T. Kamata, et al.
Continuous hyperthermic peritoneal perfusion for the treatment of peritoneal dissemination in gastric cancers and subsequent second-look operation.
Cancer, 65 (1990), pp. 65-71
[68.]
D. Elias, S. Antoun, B. Raynard, J.M. Puizillout, J.C. Sabourin, M. Ducreux, et al.
Treatment of peritoneal carcinomatosis using complete excision and intraperitoneal chemohyperthermia. A phase I-II study defining the best technical procedures.
Chirurgie, 124 (1999), pp. 380-389
[69.]
D. Elias, S. Antoun, A. Goharin, A.E. Otmany, J.M. Puizillout, P. Lasser.
Research on the best chemohyperthermia technique of treatment of peritoneal carcinomatosis after complete resection.
Int J Surg Investig, 1 (2000), pp. 431-439
[70.]
P.H. Sugarbaker.
An instrument to provide containment of intraoperative intraperitoneal chemotherapy with optimized distribution.
J Surg Oncol, 92 (2005), pp. 142-146
[71.]
M. Guerbet, J.P. Goullé, J. Lubrano.
Evaluation of the risk of contamination of surgical personnel by vaporization of oxaliplatin during the intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC).
Eur J Surg Oncol, 33 (2007), pp. 623-626
[72.]
O.A. Stuart, A.D. Stephens, L. Welch, P.H. Sugarbaker.
Safety monitoring of the coliseum technique for heated intraoperative intraperitoneal chemotherapy with mitomycin C.
Ann Surg Oncol, 9 (2002), pp. 186-191
[73.]
K. Schmid, M.I. Boettcher, J.O. Pelz, T. Meyer, G. Korinth, J. Angerer, et al.
Investigations on safety of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) with Mitomycin C.
Eur J Surg Oncol, 32 (2006), pp. 1222-1225
[74.]
P. Keshaviah, P.F. Emerson, E.F. Vonesh, J.C. Brandes.
Relationship between body size, fill volume, and mass transfer area coefficient in peritoneal dialysis.
J Am Soc Nephrol, 4 (1994), pp. 1820-1826
[75.]
D.M. Elias, L. Sideris.
Pharmacokinetics of heated intraoperative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis.
Surg Oncol Clin North Am, 12 (2003), pp. 755-769
[76.]
C.R. Rossi, M. Deraco, M. de Simone, S. Mocellin, P. Pilati, M. Foletto, et al.
Hyperthermic intraperitoneal intraoperative chemotherapy after cytoreductive surgery for the treatment of abdominal sarcomatosis: clinical outcome and prognostic factors in 60 consecutive patients.
Cancer, 100 (2004), pp. 1943-1950
[77.]
D. Baratti, S. Kusamura, A. Martinetti, E. Seregni, B. Laterza, D.G. Oliva, et al.
Prognostic value of circulating tumor markers in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Ann Surg Oncol, 14 (2007), pp. 2300-2308
[78.]
O. Glehen, V. Schreiber, E. Cotte, A.C. Sayag-Beaujard, D. Osinsky, G. Freyer, et al.
Cytoreductive surgery and intraperitoneal chemohyperthermia for peritoneal carcinomatosis arising from gastric cancer.
Arch Surg, 139 (2004), pp. 20-26
[79.]
F.N. Gilly, P.Y. Carry, A.C. Sayag, A. Brachet, G. Panteix, B. Salle, et al.
Regional chemotherapy (with mitomycin C) and intra-operative hyperthermia for digestive cancers with peritoneal carcinomatosis.
Hepatogastroenterology, 41 (1994), pp. 124-129
[80.]
P.E. Colombo, M. Boustta, S. Poujol, F. Pinguet, P. Rouanet, F. Bressolle, et al.
Biodistribution of doxorubicin-alkylated poly(L-lysine citramide imide) conjugates in an experimental model of peritoneal carcinomatosis after intraperitoneal administration.
Eur J Pharm Sci, 31 (2007), pp. 43-52
[81.]
M. Kimura, T. Konno, Y. Miyamoto, Y. Kojima, H. Maeda.
Intracavitary administration: pharmacokinetic advantages of macromolecular anticancer agents against peritoneal and pleural carcinomatoses.
Anticancer Res, 18 (1998), pp. 2547-2550
[82.]
P. Nygren, H. Fridborg, K. Csoka, C. Sundström, M. de la Torre, J. Kristensen, et al.
Detection of tumor-specific cytotoxic drug activity in vitro using the fluorometric microculture cytotoxicity assay and primary cultures of tumor cells from patients.
Int J Cancer, 56 (1994), pp. 715-720
[83.]
R. Larsson, J. Kristensen, C. Sandberg, P. Nygren.
Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia, using a fluorometric microculture cytotoxicity assay (FMCA).
Int J Cancer, 50 (1992), pp. 177-185
[84.]
H. Mahteme, A. von Heideman, B. Grundmark, B. Tholander, L. Påhlman, B. Glimelius, et al.
Heterogeneous activity of cytotoxic drugs in patient samples of peritoneal carcinomatosis.
Eur J Surg Oncol, (2007),
[85.]
Y. Yonemura, E. Bandou, T. Sawa, Y. Yoshimitsu, Y. Endou, T. Sasaki, et al.
Neoadjuvant treatment of gastric cancer with peritoneal dissemination.
Eur J Surg Oncol, 32 (2006), pp. 661-665
[86.]
P.H. Sugarbaker.
Treatment of peritoneal carcinomatosis from colon or appendiceal cancer with induction intraperitoneal chemotherapy.
Cancer Treat Res, 82 (1996), pp. 317-325
[87.]
B. Zylberberg, D. Dormont, S. Janklewicz, E. Darai, J.J. Bretel, C. Poncelet, et al.
Response to neo-adjuvant intraperitoneal and intravenous immunochemotherapy followed by interval secondary cytoreduction in stage IIIc ovarian cancer.
Eur J Gynaecol Oncol, 22 (2001), pp. 40-45
[88.]
J. Esquivel, J. Vidal-Jove, M.A. Steves, P.H. Sugarbaker.
Morbidity and mortality of cytoreductive surgery and intraperitoneal chemotherapy.
Surgery, 113 (1993), pp. 631-636
[89.]
P.H. Sugarbaker, T. Graves, E.A. DeBruijn, W.J. Cunliffe, R.E. Mullins, W.E. Hull, et al.
Early postoperative intraperitoneal chemotherapy as an adjuvant therapy to surgery for peritoneal carcinomatosis from gastrointestinal cancer: pharmacological studies.
Cancer Res, 50 (1990), pp. 5790-5794
[90.]
D.S. Alberts, P.Y. Liu, E.V. Hannigan, R. O’Toole, S.D. Williams, J.A. Young, et al.
Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.
N Engl J Med, 335 (1996), pp. 1950-1955
[91.]
M. Markman, B.N. Bundy, D.S. Alberts, J.M. Fowler, D.L. Clark-Pearson, L.F. Carson, et al.
Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group Southwestern Oncology Group, and Eastern Cooperative Oncology Group.
J Clin Oncol, 19 (2001), pp. 1001-1007
[92.]
D.K. Armstrong, B. Bundy, L. Wenzel, H.Q. Huang, R. Baergen, S. Lele, Gynecologic Oncology Group, et al.
Intraperitoneal cisplatin and paclitaxel in ovarian cancer.
N Engl J Med, 354 (2006), pp. 34-43
[93.]
T.D. Yan, L. Bijelic, P.H. Sugarbaker.
Critical analysis of treatment failure after complete cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal dissemination from appendiceal mucinous neoplasms.
Ann Surg Oncol, 14 (2007), pp. 2289-2299
[94.]
L. Bijelic, T.D. Yan, P.H. Sugarbaker.
Failure analysis of recurrent disease following complete cytoreduction and perioperative intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer.
Ann Surg Oncol, 14 (2007), pp. 2281-2288
Copyright © 2009. Asociación Española de Cirujanos
